Table 2 Confirmed best responses in assessable patients.

From: Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

 

VRda (n = 215)

Rda (n = 207)

Complete response (CR)

24.2% (52)

12.1% (25)

Very good partial response (VGPR)

50.7% (109)

41.1% (85)

VGPR or better

74.9% (161)

53.2% (110)

Partial response (PR)

15.3% (33)

25.6% (53)

Overall response rate (ORR)

90.2% (194)

78.8% (163)

Stable disease (SD)

7.0% (15)

16.4% (34)

PD or Death

2.8% (6)

4.8% (10)

  1. VRd is the bortezomib, lenalidomide, dexamethasone group and Rd is the lenalidomide dexamethasone group.
  2. aBoth SWOG and IRC stratified Cochran–Mantel–Haenszel analyses indicated improved responses with VRd (odds ratio = 0.528; P = 0.006 [ITT] odds ratio = 0.38: P = 0.001 [sensitivity analysis].
Back to article page